MZE829 — Interim data
Sep 2026–Apr 2027
With key progress made in our development programs, we are looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027, initial data from MZE782 in 2027, and additional trial initiations for both molecules next year, said Jason Coloma, Ph.D., chief executive officer of Maze.Source filing